| Logo | Name | Σ | Employees |
|---|---|---|---|
 |  InVenis Biotherapies Platelet-derived Regenerative Therapy for CNS Disorders InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis. 217 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 7 | 2 |
 |  Coave Therapeutics Coave therapeutics Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success … 86 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: Synthetic Biology | 10 | 41 |
 |  Neurolixis New treatments for central nervous system disorders Neurolixis Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of human central nervous system diseases including movement disorders, autism spectrum disorders, depression and pain. Neuroscience, Drug development, Rett Syndrome, Parkinson's disease, Biased agonism, and Orphan Drug 142 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 5 |
 | AstronauTx AstronauTx is tackling dementia through improving brain physiology AstronauTx is at the forefront of a novel approach to treating neurodegenerative diseases. We have a unique portfolio of small-molecule therapeutics to restore dysregulated physiology to both improve symptoms and modify disease. 101 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 2 | 15 |
 | Harness Therapeutics Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases Unlocking New Targets to Transform the Treatment of Neurodegenerative Diseases neurodegeneration, RNA therapeutics, physiological upregulation, post-transcriptional upregulation, mRNA, ASO, and SINEUP 279 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 32 |
 | SynaptixBio Ltd. Developing therapies for severe leukodystrophies Overview SynaptixBio is a rare disease biotech company that is pioneering ground-breaking treatments for severe leukodystrophies and other childhood neurodegenerative diseases. SynaptixBio’s mission is to deliver gene therapies for fatal leukodystrophies in children caused by loss of function or mutation in a single gene. Using a breadth of platforms including antisense oligonucleotide (ASO)-based technology, we can silence the expression of the toxic gene to reverse disease progression. This approach will create life saving treatments for severe genetic diseases that affect the central nervous system. Pharmaceutical, Biotech, Leukodystrophy, Rare Disease, H-ABC, Hypomyelination, Basal Ganglia, Cerebrllum, Neurology, … 59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 2 | 5 |
 | PepGen Better Technology. Better Delivery. Developing a new generation of disease-modifying therapies. Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders. Biotechnology, Chemistry, Biology, Bioscience, Life sciences, and Therapeutics 436 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology | 1 | 89 |
 | Rewind Therapeutics Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition and movement, among others. The causes of damage may be genetic, a result of infectious or autoimmune disease or from exposure to toxic agents or other forms of brain injury. There is no cure for demyelinating diseases. The Company was founded by KU Leuven’s Centre for Drug Design and Discovery (CD3) and … 5 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology | 0 | 18 |
 | uniQure Transforming the lives of patients through gene therapy uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases. aav, Huntington's disease, gene therapy, ALS, epilepsy, and Fabry disease 160 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology | 2 | 334 |